Researchers at Immunocore Limited today announced that IMCgp100, a targeted therapeutic for the treatment of advanced metastatic melanoma, has received regulatory and ethics approval and has opened enrolment for clinical trials in the England and USA.
IMCgp100 is the first clinical candidate originating from Immunocore’s innovative ImmTAC technology platform and a new treatment could benefit many thousands of patients diagnosed with skin cancer each year.
Professor Mark Middleton of the NIHR Biomedical Research Centre, Oxford said: “We need new treatment options for patients with metastatic melanoma that not only extend lives but also improve quality of life. This clinical trial will generate the first data on this promising novel reagent IMCgp100”.
Click here for more information.